Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …

Human malignancies are often the result of overexpressed and constitutively active receptor
and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor …

The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in
approximately 15% to 20% of patients with intrahepatic cholangiocarcinoma. Currently …

Cholangiocarcinoma is a highly aggressive and lethal malignancy, with limited treatment
options available. Recently, FGFR inhibitors have been developed and utilized in FGFR …

There is growing evidence that tyrosine kinase inhibitors (TKIs) may be associated with an
increased risk of arterial events. We performed a meta-analysis to estimate the incidence of …

Tyrosine kinase inhibitors (TKIs) have revolutionized the prognosis of chronic myeloid
leukemia. With the advent of highly efficacious therapy, the focus has shifted toward …

Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of
chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life …

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid
leukemia, inducing deep molecular responses, largely improving patient survival and …

Patients with cancer are at high risk for both venous and arterial thrombotic complications. A
variety of factors account for the greater thrombotic risk, including the underlying malignancy …

Biliary tract cancer (BTC) is a leading cause of cancer-related death, due to the limited
benefits of current systematic therapies and the heterogeneity of the tumor itself. High …